[Relationship between Immune Differentiation Antigen and Minimal Residual Disease in Childhood B-ALL]

To determine whether immune differentiation antigen is related with clinical features and minimal residual disease (MRD) in childhood B-cell precursor acute lymphoblastic leukemia (B-ALL), who were treated with CCCG-ALL-2015 protocol.

A retrospective analysis was conducted in 132 B-ALL children, Multiparametric flow cytometry was used to analyze the immunophenotypes. The children were divided into 2 groups by MRD>0.1% on d 19 and / or d 46 after chemotherapy. The Wilcoxon rank-sum test and χ² test were used for the comparison between groups, and P<0.05 was considered statistically significant.

CD19 (100%), CD22 (99.3%) and cCD79a (97.9%) were specific markers for patients with B-ALL, the CD13 and CD33 were mainly cross myeloid antigen. The significant differences were found between CD45^- and CD45⁺ in WBC counts when being firstly diagnosed (Z=6.845, P<0.01), risk stratification (χ²=8.260, P<0.05) and prednisone poor responder (χ²=18.420, P<0.01). Significant differences were found between CD10^- and CD10⁺ in age (Z=6.253, P<0.05), risk stratification (χ²=6.699, P<0.05) and MRD (χ²=4.951, P<0.05).

In CCCG-ALL-2015 protocol, the CD10 relates with the early MRD, suggesting a better prognosis, and reducing the adverse effects of CD20 and cross myeloid antigen on prognosis.